DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Saturday, 11 June 2016

Roba Jfeily, Teva Pharmaceutical Industries Ltd Israel

Roba Jfeily

Roba Jfeily

Teva Pharmaceutical Industries Ltd Israel







The Bloomfield Science Museum Jerusalem
(7 months)


Jerusalem College of Engineering

Bachelor of Applied Science (B.A.Sc.)

Pharmaceutical Engineering


Synthesis of backbone cyclic peptide as potential drug for rheumatoid arthritis (RA)


מתגבשים - טבע — ‎with ‎‎Nehad Steti, Rafi Port, Matan Maman, ‎Arnold Izraelov, ‎Revital Kaner, ‎ענת שאער‎‎‎‎ and Lina Rozin-Ben Baruch‎ at ‎חוף נווה מדבר ים המלח‎.‎


 Teva Pharmaceutical Industries Ltd Israel

Map of ‫טבע‬‎
Corporate Office
Address: Basel St 5, Petah Tikva, 4951033, Israel
Phone:+972 3-926-7267



Petah Tikva, ISRAEL

  1. Petah Tikva – Wikipedia, the free encyclopedia

    Petah Tikva (Hebrew: פֶּתַח תִּקְוָה, IPA: [ˈpetaχ tikˈva], “Opening of Hope”) known as Em HaMoshavot (“Mother of the Moshavot”), is a city in the Central …

Khayim Ozer Street, Petah Tikva, Israel



Inbal Hesseg


Inbal Hesseg





Technical Support

013 Netvision
(1 year 1 month)Haifa Area, Israel
Technical support representative ,interact with customers,diagnose and resole hardware and software issues involving internet connectivity.


Technion - Israel Institute of Technology

Bachelor of Science (BSc), Chemistry







Dr. Larry Keefer

Dr. Larry Keefer
Drug Design
Dr. Keefer received his Ph.D. in organic chemistry from the University of New Hampshire in 1966 and held research positions at the Chicago Medical School and the University of Nebraska College of Medicine before joining the NCI staff in 1971.
Go to Larry's Page

Dr. Larry Keefer

Dr. Larry Keefer
Drug Design

Research Summary

Link to Diazeniumdiolate Chemistry Database

Chemistry and Biology of Nitric Oxide

Nitric oxide (NO) is a potent and multifaceted bioregulatory agent. This project is aimed at finding ways to target NO to specific sites in the body for important research and/or therapeutic applications.

Our strategy in pursuing this goal is to begin by characterizing the fundamental chemistry of the NO-releasing diazeniumdiolates (compounds containing the [N(O)NO] functional group). We then attempt to exploit our accumulating knowledge in this area as a platform for solving problems in biomedical research and clinical medicine. We are currently pursuing basic research investigations into the structure, spectra, dissociation to NO and/or HNO, alkylation, arylation, photodegradation, and general reactivity of the diazeniumdiolate functional group with an eye toward designing prodrugs that are stable at physiological pH but that can be activated to generate NO or HNO by enzymatic action. An example is AcOM-PYRRO/NO, an esterase-sensitive diazeniumdiolate that penetrates the cell and generates NO within the cytoplasm on esterase-induced hydrolysis; AcOM-PYRRO/NO has proved to be two orders of magnitude more potent as an inducer of apoptosis in HL-60 leukemia cells in culture than the spontaneously dissociating parent ion, PYRRO/NO. Other achievements include the design of agents that can be activated for NO release by enzymes of the glutathione S-transferase, glycosidase, and cytochrome P450 families. Other recently introduced diazeniumdiolates have been designed to target nitric oxide delivery to macrophages for antimicrobial activity. Proof-of-concept studies that underscore the substantial clinical promise of these compounds include: inhibition of restenosis after angioplasty; preparation of thromboresistant medical devices; and inhibition of tumor growth in in vivo models. The results of the animal experiments suggest that a variety of problems in clinical medicine might be solved by mining the extensive library of possible diazeniumdiolate structures.

Current collaborators in these efforts include: Sonia Donzelli, Univ. of Hamburg-Eppendorf, Hamburg, Germany; Astrid Weyerbrock, Uni-Klinik Freiburg, Germany; Stefan Chlopicki, Jagellionian Center for Experimental Therapeutics, Krakow, Poland; Jeffrey Deschamps, Naval Research Laboratory; Xinhua Ji, NIH; Melina Kibbe, Northwestern University; Paul Shami, University of Utah; David Wink, NIH; and Regina Ziegler, NIH.
1 - 5 of 242 results
1)  Biswas D, Hrabie JA, Saavedra JE, Cao Z, Keefer LK, Ivanic J, Holland RJ.
Aminolysis of an N-Diazeniumdiolated Amidine as an Approach to Diazeniumdiolated Ammonia.
J. Org. Chem. 79: 4512-4516, 2014. [Journal]
2)  Bharadwaj G, Benini PG, Basudhar D, Ramos-Colon CN, Johnson GM, Larriva MM, Keefer LK, Andrei D, Miranda KM.
Analysis of the HNO and NO donating properties of alicyclic amine diazeniumdiolates.
Nitric Oxide. 42: 70-8, 2014. [Journal]
3)  Fuhrman BJ, Xu X, Falk RT, Dallal CM, Veenstra TD, Keefer LK, Graubard BI, Brinton LA, Ziegler RG, Gierach GL.
Assay reproducibility and interindividual variation for 15 serum estrogens and estrogen metabolites measured by liquid chromatography-tandem mass spectrometry.
Cancer Epidemiol. Biomarkers Prev. 23: 2649-57, 2014. [Journal]
4)  Holland RJ, Klose JR, Deschamps JR, Cao Z, Keefer LK, Saavedra JE.
Direct reaction of amides with nitric oxide to form diazeniumdiolates.
J. Org. Chem. 79: 9389-93, 2014. [Journal]
5)  Kaczmarek MZ, Holland RJ, Lavanier SA, Troxler JA, Fesenkova VI, Hanson CA, Cmarik JL, Saavedra JE, Keefer LK, Ruscetti SK.
Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
Leuk. Res. 38: 377-82, 2014. [Journal]

Dr. Joe Barchi

Dr. Joe Barchi
Structural Glycoconjugate Chemistry and NMR
Dr. Barchi received his Ph.D. in Organic Chemistry from the University of Hawaii with Richard E. Moore and did 2 years of postdoctoral work at Duke University with Bert Fraser-Reid. He then joined the NCI as a staff fellow in 1988, was promoted to staff scientist and then to senior scientist in 2002. His main research interests are in synthetic medicinal chemistry as it relates to carbohydrate-based drug design, and the high-resolution structural analysis of sugars, glycopeptides and small molecule drug candidates by NMR spectroscopy.
Go to Joe's Page

Dr. Joe Barchi

Dr. Joe Barchi
Structural Glycoconjugate Chemistry and NMR

Research Summary

Multivalent Presentation of Tumor-Associated Carbohydrate Antigens (TACA) and TACA-Peptide Conjugates as Modulators of Tumor Cell Adhesion and Novel Immunogens

Carbohydrates are presented on the surface of cells primarily in covalent linkages to proteins (glycoproteins, proteoglycans) or lipids (glycolipids, gangliosides. These diverse groups of oligosaccharide chains function to stabilize protein structures, facilitate protein transport or clearance, and mediate cell adhesion. Cell-surface glycans may reveal or mask peptide epitopes on proteins or be recognized as immunogenic structures themselves. During oncogenesis, the cell-surface glycans on tumor cells are transformed relative to the normal phenotype through modified expression of the enzymes involved in the cell's glycoprocessing machinery. These aberrations are a hallmark of highly tumorigenic and metastatic cell types. The cascade of events leading to tumor metastasis is marked by the alternate adhesion and release of the tumor cell with a variety of surrounding cell types. The binding between tumors and other cell types is often mediated by carbohydrate-protein (lectin) interactions involving the aberrant glycans expressed on tumor cells. Inhibition of these adhesion events could slow or prevent metastatic spread. In addition, some of these tumor cell glycans are TACA's that are recognized as non-self by the immune system and have thus been used as components in vaccine constructs that are in clinical trials. Since it is well known that monovalent sugar-protein binding is a very weak interaction, inhibitors of these events utilize 'multivalency' (multiple copies of the carbohydrate ligand) to enhance the strength of this effect. We are exploring ways to synthesize novel templates on which to place multiple copies of the Thomsen Freidenreich (Tf) antigen, a disaccharide O-linked to proteins found on the cell surface that is present in >90% of carcinomas but rarely found in normal tissue. We have developed a new synthesis of this antigen that is equipped with a conjugatable linker to attach to macromolecules or other surfaces. We attached Tf antigen to gold surfaces and showed that this construct attached strongly to a Tf-binding peptide. In addition, our group discovered a new synthesis of Tf-encapsulated Quantum Dots (QD). These are new semiconductor nanocrystals that have size-dependent optical properties that make them extremely useful as biological imaging agents. These novel sugar-coated particles are also being explored as potential immunogens to raise high titer antibodies to Tf antigen. The preparation of glycopeptides containing the Tf disaccharide that are displayed on gold or QD particles is now being investigated. It is hoped that the combination of the peptide and the covalently linked carbohydrate will generate a glycopeptide-specific immune response that will be mmore powerful than either single antigen alone.

Conformational Analysis of Drug Candidates by NMR Spectroscopy

The LMC synthesizes small molecule agents potential anticancer or antiviral therapeutics. Our section uses NMR spectroscopy to determine 3-dimensional connformations of many of these candidates as an aid to structure-based drug design. Currently, a major area of research has focused on the global conformational changes imparted to small DNA duplexes by inclusion of conformationally constrained base pairs. These nucleoside analogues were synthesized in the LMC (see Marquez group home page) and incorporated into a standard B-DNA sequence. The analogues were designed to force an A-DNA like motif in the center of the duplex. NMR data has allowed us to define any additional bending in the overall duplex that is caused by the base 'mutations'. The goal is to design oligonucleotides that are predisposed to different bend angles and may mimic the deformations caused when specific gene sequences bind to proteins (e.g., transcription factors)
1 - 5 of 96 results
1)  Ambre Shailesh, Barchi Joseph.
Stine Keith, eds.
Carbohydrate Nanotechnology and its Applications for the Treatment of Cancer. In: Carbohydrate Nanotechnology.
Hoboken, NJ: John Wiley and Sons; 2015. p. 335-368. [Book Chapter]
2)  Huang X, Barchi JJ.
Carbohydr. Res. 405: 1, 2015. [Journal]
3)  Biswas S, Medina SH, Barchi JJ.
Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles.
Carbohydr. Res. 405: 93-101, 2015. [Journal]
4)  Glinskii OV, Li F, Wilson LS, Barnes S, Rittenhouse-Olson K, Barchi JJ, Pienta KJ, Glinsky VV.
Endothelial integrin a3ß1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane.
Oncotarget. 5: 1382-9, 2014. [Journal]
5)  Briñas RP, Maetani M, Barchi JJ.
A survey of place-exchange reaction for the preparation of water-soluble gold nanoparticles.
J Colloid Interface Sci. 392: 415-21, 2013. Full Text Article. [Journal]

Dr. Joel Schneider

Dr. Joel Schneider
Peptide Design and Materials
Dr. Schneider received his Ph.D. in Organic Chemistry from Texas A&M University with Jeffery Kelly and then went on to the University of Pennsylvania School of Medicine, Department of Biochemistry and Biophysics where he was a George W. Raiziss Fellow with William DeGrado studying protein design. In 1999, he began his independent career at the University of Delaware as an assistant professor of Chemistry and Biochemistry and was promoted to associate and then full professor in 2009 with a secondary appointment in Materials Science and Engineering. He joined the NCI in 2010 as lab Chief of the newly established Chemical Biology Laboratory. He currently serves as Editor in Chief of Biopolymers-Peptide Science, the journal of the American Peptide Society.
Go to Joel's Page

Dr. Joel Schneider
Peptide Design and Materials

Research Summary

The Schneider group designs and characterizes novel materials for use in tissue regenerative therapy, parenteral delivery of therapeutics, delivery of cells, and antibacterial therapy. We are particularly interested in peptide and protein-based hydrogel materials formed by self-assembly mechanisms. Our work spans molecular conception, materials synthesis, nano- and bulk mechanical materials characterization, cell-material interactions, biocompatibility, and assessment of performance efficacy. Our basic research establishes how material composition and structure influences material function, and lays the foundation to ultimately translate materials to the clinic.
1 - 5 of 88 results
1)  Medina Scott H, Schneider Joel P.
Cancer cell surface induced peptide folding allows intracellular translocation of drug.
J+Control+Release. 209: 317-26, 2015. [Journal]
2)  Medina Scott H, Li Sandra, Howard O M Zack, Dunlap Micah, Trivett Anna, Schneider Joel P, Oppenheim Joost J.
Enhanced immunostimulatory effects of DNA-encapsulated peptide hydrogels.
Biomaterials. 53: 545-53, 2015. [Journal]
3)  Micklitsch C, Medina S, Yucel T, Nagy-Smith K, Pochan D, Schneider J.
Influence of hydrophobic face amino acids on the hydrogelation of β-hairpin peptide amphiphiles.
Macromolecules. 48: 1281-1288, 2015. [Journal]
4)  Sathaye S, Mbi A, Sonmez C, Chen Y, Blair DL, Schneider JP, Pochan DJ.
Rheology of peptide- and protein-based physical hydrogels: Are everyday measurements just scratching the surface?.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 7: 34-68, 2015. [Journal]
5)  Schneider JP.
Another year behind us.
Biopolymers. 102: vii, 2014. [Journal]

Dr. Craig Thomas

Dr. Craig Thomas
Dr. Craig Thomas
Chemistry Technology

Craig Thomas received his BS from the University of Indianapolis in 1995 and received an MS degree and Ph.D. from Syracuse University in 2000. He then undertook a post-doctoral work in the laboratories of Dr. Sidney Hecht at the University of Virginia where he earned a fellowship through the American Cancer Society. From there, he moved the NIH where he directed the chemical biology core of the National Institute of Diabetes and Digestive and Kidney Diseases. In 2007, he moved to the NIH Chemical Genomics Center (currently the NIH Center for Advancing Translational Sciences) where he serves as the group leader of chemistry technologies.
Go to Craig's Page
Dr. Craig Thomas
Chemistry Technology

Research Summary

For more information about Chemistry Technology at NCATS, please go to: http://www.ncats.nih.gov/research/reengineering/ncgc/chemtech/chem-tech.html
1 - 5 of 104 results
1)  Jiang J, McCoy JG, Shen M, Leclair CA, Huang W, Negri A, Li J, Blue R, Harrington AW, Naini S, David G, Choi W, Volpi E, Fernandez J, Babayeva M, Nedelman MA, Filizola M, Coller BS, Thomas CJ.
A novel class of ion displacement ligands as antagonists of the aIIbß3 receptor that limit conformational reorganization of the receptor.
Bioorg. Med. Chem. Lett. 24: 1148-53, 2014. [Journal]
2)  Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.
Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 111: 11365-70, 2014. [Journal]
3)  Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C.
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Breast Cancer Res. 16: R67, 2014. [Journal]
4)  Thomas CJ, McKew JC.
Editorial: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government.
Curr Top Med Chem. 14: 291-3, 2014. [Journal]
5)  Shukla S, Chufan EE, Singh S, Skoumbourdis AP, Kapoor K, Boxer MB, Duveau DY, Thomas CJ, Talele TT, Ambudkar SV.
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein.
Leukemia. 28: 961-4, 2014. [Journal]

1) Beutler JA, Chung S, Jiang JK, Legrice SF, Thomas CJ, Wilson JA (submitted in 2011) Tropolone Compounds For Treating Or Preventing Retroviral Infection.
Patent issued: 8,993,768 (US in 2015).
Patent pending: PCT/US2012/037208 (PC application).

2) FitzGerald D, Jiang JK, O'Shea JJ, Onda M, Pastan IH, Thomas CJ (submitted in 2010) Inhibition Of Antibody Responses To Foreign Proteins.
Patent pending: PCT/US2011/024382 (PC application).
Patent pending: PCT/US2011/024382 (PC application).

Dr. Martin Schnermann

Dr. Martin Schnermann
Organic Synthesis

Dr. Schnermann attended Colby College and graduated in 2002 with degrees in Chemistry and Physics. At Colby, he worked with Prof. Dasan Thamattoor in the areas of physical organic chemistry and photochemistry. After a year at Pfizer Research and Development (Groton, CT) as an associate in the medicinal chemistry division, he moved to the Scripps Research Institute. During his graduate studies, he performed research on the total synthesis and biological evaluation of anticancer natural products with Prof. Dale Boger and obtained a Ph.D. in 2008. He then completed an NIH-postdoctoral fellowship with Prof. Larry Overman at the University of California, Irvine. At Irvine, he developed light-mediated reactions to enable the synthesis of complex natural products. In addition, working with Prof. Christine Suetterlin, he pursued chemical biology and imaging studies of organelle specific probes. In 2012, Dr. Schnermann joined the NCI where his research focuses on the synthesis and development of new small-molecule imaging agents for cancer treatment and diagnosis.
Go to Martin's Page

Research Summary

Near-IR Uncaging Chemistry: Discovery and Applications
Many key fundamental and applied questions in biology require unraveling issues relating to the spatial and temporal organization of multi-cellular systems. The combination of photocaged small molecule probes and the spatially controlled application of light could in principle provide key insights. However, existing photoremovable caging groups are often not suitable, particularly for organismal applications. This is due to the general requirement of UV or blue light, which suffers from associated toxicity and poor tissue penetration. By contrast, light between 650 and 900 nm, often referred to as the near-IR window, is cytocompatible and has significant tissue penetration (~centimeters). My group develops new single photon near-IR uncaging methods. This is a challenging chemistry problem because these wavelengths have only modest photonic energy. Our approach is been to define and then take advantage of photochemical reactions of long-wavelength fluorophores. In our most advanced project, we have shown that the photooxidative reactivity of heptamethine cyanines can be used for small molecule drug delivery. We have also shown that the photoredox ligand exchange of silicon phthalocyanines can be used for hypoxia-selective drug delivery. We use our methods towards two key unmet challenges in biology: (1) the development of a general theranostic approach for site-specific optical imaging and drug delivery and (2) the spatial and temporal regulation of gene expression to track and control cell fate.

Modern Synthetic Approaches for Small Molecule Imaging
There is a significant need for improved near-IR fluorophores for emerging applications in basic and applied biomedical science. Existing molecules are often prepared through inefficient classical synthetic methods that suffer from poor substrate scope and harsh reaction conditions. The limitations of existing methodologies dictate that researchers must choose from a small collection of probes whose chemical and physical properties are not ideal. We create reactions that enable the efficient preparation of novel near-IR fluorophores. We then use this chemistry to develop molecules with excellent chemical and photochemical stability and improved optical properties. These molecules are then applied towards several key cancer-related imaging applications. In related efforts, we are mining the structural diversity of natural products for light emitting scaffolds to develop broadly useful optical probes. Key to this work is the development of concise total syntheses to access compounds of interest.
1 - 5 of 11 results
1)  Nani RR, Shaum JB, Gorka AP, Schnermann MJ.
Electrophile-integrating smiles rearrangement provides previously inaccessible c4"-o-alkyl heptamethine cyanine fluorophores.
Org. Lett. 17: 302-5, 2015. [Journal]
2)  Chan Susanna T S, Patel Paresma R, Ransom Tanya R, Henrich Curtis J, McKee Tawnya C, Goey Andrew K L, Cook Kristina M, Figg William D, McMahon James B, Schnermann Martin J, Gustafson Kirk R.
Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α.
J.+Am.+Chem.+Soc. 137: 5569-75, 2015. [Journal]
3)  Gorka AP, Nani RR, Zhu J, Mackem S, Schnermann MJ.
A Near-IR Uncaging Strategy Based on Cyanine Photochemistry.
J. Am. Chem. Soc. 136: 14153-14159, 2014. Full Text Article. [Journal]
4)  Schnermann MJ, Shenvi RA.
Syntheses and biological studies of marine terpenoids derived from inorganic cyanide.
Nat Prod Rep. 2014. [Journal]
5)  Schnermann MJ, Overman LE.
A Concise Synthesis of (-)-Aplyviolene Facilitated by a Strategic Tertiary Radical Conjugate Addition.
Angew. Chem. Int. Ed. Engl. 2012. [Journal]

1) Schnermann MJ, Gorka AJ, Kobayashi HJ, Nani RJ (submitted in 2015) Near-ir Light-cleavable Conjugates And Conjugate Precursors.
Patent pending: 62/204,381 (US application).
Patent pending: 62/204,381 (US application).

2) Gustafson KR, Chan SR, Figg WR, McMahon JR, Patel PR, Schnermann MR (submitted in 2015) Hypoxia-inducible Factor 1 Hif-1 Inhibitors.
Patent pending: 62/144,182 (US application).
Patent pending: 62/144,182 (US application).